Skip to main content

Table 5 All-cause and rheumatoid arthritis-related healthcare costs during 1-year follow-up

From: Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

Healthcare costsa per patient

Responders (n = 2337)

Nonresponders (n = 2337)

p Valueb

Mean (SD)

Median (range)

Mean (SD)

Median (range)

Medical, all-cause

 Total medical

7581 (15,575)

2123 (0 – 301,318)

13,318 (23,433)

4238 (0 – 337,588)

<0.001

 Inpatient hospitalizations

1509 (9,676)

0 (0 – 239,362)

3264 (14,549)

0 (0 – 314,893)

<0.001

 Joint replacement surgeries

338 (3415)

0 (0 - 77,382)

656 (5403)

0 (0 - 102,929)

0.016

 Infections

149 (2154)

0 (0 - 81,742)

826 (7412)

0 (0 - 225,407)

<0.001

 CV events

277 (6198)

0 (0 - 239,362)

464 (6482)

0 (0 - 211,055)

0.312

 ED encounters

207 (962)

0 (0 – 16,039)

460 (1909)

0 (0 – 40,264)

<0.001

 Outpatient visits

5863 (10,666)

1922 (0 – 148,294)

9565 (15,840)

3460 (0 – 252,428)

<0.001

 Physician office visits

1066 (877)

863 (0 – 15,573)

1424 (1237)

1118 (0 – 13,152)

<0.001

 Rheumatologist office visits

304 (342)

221 (0 – 3715)

357 (455)

232 (0 – 4284)

<0.001

 Physical/occupational therapy

131 (534)

0 (0 - 7567)

222 (851)

0 (0 - 14,319)

<0.001

 DME

393 (10,188)

0 (0 - 484,558)

486 (4609)

0 (0 - 122,724)

0.686

 Imagingc

930 (2596)

210 (0 – 46,467)

1559 (3971)

350 (0 – 48,412)

<0.001

Pharmacy, all-cause (excluding biologics)

1698 (2728)

903 (0 – 22,905)

2052 (3370)

1004 (0 – 41,748)

<0.001

Total, all-cause (medical plus pharmacy, excluding biologics)

9278 (16,142)

3919 (0 – 306,913)

15,370 (24,447)

6599 (0 – 348,118)

<0.001

Medical, RA-related

4498 (11,150)

590 (0 - 141,903)

7845 (16,300)

889 (0 - 282,902)

<0.001

Pharmacy, RA-related

21,852 (9572)

23,042 (0 – 77,237)

13,273 (10,131)

12,445 (0 – 59,331)

<0.001

 csDMARDs

214 (376)

87 (0 – 6992)

181 (360)

64 (0 – 6649)

0.002

 Biologics

21,808 (9719)

22,979 (0 – 77,220)

13,193 (10,212)

12,337 (0 – 68,752)

<0.001

Total, RA-related (medical and pharmacy)

26,350 (10,196)

24,668 (191 – 142,091)

21,118 (16,725)

18,716 (0 – 285,900)

<0.001

Total, all-cause (medical plus pharmacy, including biologics)

31,087 (15,556)

28,268 (2017 - 332,724)

28,563 (24,600)

23,701 (0 - 350,986)

<0.001

  1. Abbreviations: csDMARD Conventional synthetic disease-modifying antirheumatic drug, CV Cardiovascular, DME Durable medical equipment, ED Emergency department, RA Rheumatoid arthritis
  2. a Plan-paid costs in 2014 U.S. dollars, assessed over the first year postindex
  3. b χ2 tests were used to determine statistical differences across categorical variables; t tests were used for continuous variables. In addition, a nonparametric bootstrap was used to calculate a second set of p values for comparisons of key mean cost metrics; these p values were similar to the ones derived from the t tests. The table therefore reports the t test p values
  4. c Imaging included radiographs, magnetic resonance imaging, and other types of imaging
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us